Pfizer’s men B vaccine shows promise in phase 2.
D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007223:Infant; D008589:Meningococcal Infections / Q000382:microbiology* / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines; D014614:Vaccines, Synthetic